-
Dabrafenib
Zita reAPI Indication Innovator Patent Expiry Date (The US) Dabrafenib -
Aprocitetan
Zita reAPI Indication Innovator Patent Expiry Date (The US) Aprocitetan -
Etrasimod
Zita reAPI Indication Innovator Patent Expiry Date (The US) Etrasimod Ulceratuve Colitis (UC) Arena(Pfizer) Kurume.05,2030 -
Tirzepatide
Zita reAPI Indication Innovator Patent Expiry Date (The US) Tirzepatide Type 2 chirwere cheshuga, kuderedza uremu Eli Lilly Ndira 05,2036 -
Semaglutide
Zita reAPI Indication Innovator Patent Expiry Date (The US) Semaglutide Type2 chirwere cheshuga, kuderedza uremu Novo Nordisk Zvita.05,2031 -
Oteseconazole
Zita reAPI Indication Innovator Patent Expiry Date (The US) Oteseconazole Kuderedza kuwanda kwezviitiko zve zvinowanzoitika vulvovaginal candidiasis
Nhoroondo yeMycoviaPharmaceuticals Apr.22,2031 -
Finerenone
Zita reAPI Indication Innovator Patent Expiry Date (The US) Finerenone Chirwere cheshuga nephropathy Bayer Kubvumbi.12,2029 -
Vibegron
Zita reAPI Indication Innovator Patent Expiry Date (The US) Vibegron OAB Urovant Zvita.01,2030 -
Capivasertib
Zita reAPI Indication Innovator Patent Expiry Date (The US) Capivasertib kenza yemazamu AstraZeneca Mar.10.2030 -
Resmetirom
Zita reAPI Indication Innovator Patent Expiry Date (The US) Resmetirom NASH Roche Sep.12,2026 -
Darolutamide
Zita reAPI Indication Innovator Patent Expiry Date (The US) Darolutamide kurapwa kwekenza yeprostate Bayer Kurume. 25,2033 -
Upadacitinib
Zita reAPI Indication Innovator Patent Expiry Date (The US) Upadacitinib Atopic Dermatitis Nhoroondo ye ABBIE INC Zvita.01,2030